

UNCLASSIFIED

AD 4 3 9 2 5 3

DEFENSE DOCUMENTATION CENTER

FOR

SCIENTIFIC AND TECHNICAL INFORMATION

CAMERON STATION, ALEXANDRIA, VIRGINIA



UNCLASSIFIED

NOTICE: When government or other drawings, specifications or other data are used for any purpose other than in connection with a definitely related government procurement operation, the U. S. Government thereby incurs no responsibility, nor any obligation whatsoever; and the fact that the Government may have formulated, furnished, or in any way supplied the said drawings, specifications, or other data is not to be regarded by implication or otherwise as in any manner licensing the holder or any other person or corporation, or conveying any rights or permission to manufacture, use or sell any patented invention that may in any way be related thereto.

439253

CATALOGED BY DDC

AS AD NO.

64-13 J-166
~~SEMI-ANNUAL~~ REPORT ON

GRANT
CONTRACT NO DA-CRD-AG-892-544-63-08

INCLUSIVE DATES 18 April 1963 TO 17 October 1963

SUBJECT OF INVESTIGATION

STUDIES ON IMMUNOLOGICAL
DIAGNOSIS AND CHEMOTHERAPY
OF PARAGONIMIASIS
(LUNG FLUKE DISEASE)

RESPONSIBLE INVESTIGATOR

Dr. Munao Yokogawa
Professor of Chiba University
Department of Parasitology
School of Medicine
Chiba University
Chiba, Japan.

MAY 12 1964

U.S. Army Research & Development Group (9984) (Far East)
Office of the Chief of Research and Development
United States Army
APO 343

439253

D-I-S-T-R-I-B-U-T-I-O-N

The distribution of this report as made by USA R&D Gp (FE)
is as follows:

Army Research Office, 3045 Columbia Pike, Arlington 4, (4)✓
Virginia. ATTN: Chief Research Programs Office

Army Attache, American Embassy, Tokyo, Japan (1)

Office of Primary Scientific Liaison (4)
U.S. Army Medical Research & Development Command
ATTN: Chief, Preventive Medicine Research Branch, OTSG
Washington, D. C. 20315

~~Office of Scientific Cooperation~~ ()

INTERIM REPORT ON

CONTRACT NO DA-CRD-AG-892-544-63-G8

INCLUSIVE DATES 18 April 1963 TO 17 October 1963

SUBJECT OF INVESTIGATION

**STUDIES ON IMMUNOLOGICAL
DIAGNOSIS AND CHEMOTHERAPY
OF PARAGONIMIASIS
(LUNG FLUKE DISEASE)**

RESPONSIBLE INVESTIGATOR

Dr. Munao Yekogawa

**Professor of Chiba University
Department of Parasitology
School of Medicine
Chiba University
Chiba, Japan**

Chiba University
School of Medicine
Dept. of Parasitology

Muneo Yokogawa
Professor of Chiba University

Contract No.
DA-CRD-A3-S92-544-63-08

Date: 18, October 1963

Interim Report

Abstract report of the progress and phase of the work for one year from 18 April 1963 through 17 April 1964, and studied during the period from 18 April 1963 to 17 October 1963.

1. Comparison of the efficacies of Bitin-s-oxide with Bitin.

This study was designed to compare the efficacy of Bitin-s-oxide which was newly prepared as the derivative of Bitin with that of Bitin as follows;

No. of cases	drugs	daily dose	method of administration
9	Bitin	10 mg/kg	orally. every other day for 10 times
9	Bitin-s-oxide	10 mg/kg	"
7	Bitin	20 mg/kg	"
7	Bitin-s-oxide	20 mg/kg	"

The follow-up observations with stool examination, Complement-fixation test and Chest X-Ray examination were made at one month, 3 months, 6 months and 12 months after treatment.

The decision of complete cure was given to those cases in which no Paragonimus eggs were found in stools for more than 6 months after treatment.

Complete cure was observed in all of 9 cases receiving 10 mg/kg of Bitin-s-oxide but the one exception was found among 9 cases receiving 10 mg/kg of Bitin as shown in Table 1.

In the group given 20 mg/kg of Bitin-s-oxide a cure was observed in all of 7 cases and in the group given 20 mg/kg of Bitin a cure was also observed in all of 7 cases as shown in Table.

The changes of Antibody titers in Complement-fixation test were also shown in Table 1 and 2.

In the groups given 10 mg/kg of Bitin and Bitin-s-oxide, except one relapsed case, all of the cases showed the decrease of antibody titers in Complement-fixation test for 12 months after treatment. However, one case which showed no changes of antibody titer in Complement-fixation reaction for 6 months after treatment was found each in the groups given 20 mg/kg of Bitin and Bitin-s-oxide, although the examination for eggs showed negative results for 6 months after treatment.

Further observation are now being made.

Any significant difference in the frequency of side effects between Bitin and Bitin-s-oxide was not observed.

The changes of the abnormal shadows in the Chest X-Ray for 12 months after treatment were also shown in Table 3.

2. Epidemiological survey for paragonimiasis in Noto district of Ishikawa Prefecture, Japan.

The epidemiological survey for paragonimiasis using intradermal tests, Complement-fixation tests and stool examinations were conducted in Takahama-machi and Shika-machi, Noto district of Ishikawa Prefecture, Japan.

The results obtained in this survey are as follows:

In school children of Takahama-machi, 44(2.6 %) out of 1,722 showed positive or doubtful skin reactions. Among those 44 cases which showed positive or doubtful skin reactions, 13 cases were positive for complement-fixation tests and 4 cases were positive for Paragonimus eggs in stool as shown in Table 4.

In Shika-machi, 26(2.5 %) out of 1,023 inhabitants were positive or doubtful for intradermal reaction, and 4 of them were positive for complement-fixation tests as shown in Table 4.

Stool examination of those individuals who showed positive skin reaction are now under examination.

Table 1. Changes of dilution titer of Antiserum in Complement-fixation test on the individuals before and after treatment with daily dose of 10 mg/kg of Bitin and Bitin-s-oxide.

Case No.	Name	Age	Sex	Before treatment	During treatment	Immediately after treatment	After treatment			
							1M.	3M.	6M.	12M.
(Bitin)										
1	S.S.	9	F	>X160 (38)		X160 (0)	>X160 (0)	X100 (0)	X 31 (0)	X 14 (0)
2	H.M.	11	M	X 25 (8)	X 20 (0)	(0)	(0)	(0)	(0)	(0)
3	H.A.	13	M	>X160 (95)	(0)	>X160 (0)	>X160 (0)	X 87 (0)	X 27 (0)	X13 (0)
4	K.O.	14	M	X 67 (47)	X 51 (0)	X 67 (0)	X 66 (0)	X 17 (0)	(0)	(0)
5	Y.M.	14	M	X 33 (14)	X 26 (0)	X 24 (0)	(0)	X 17 (0)	(0)	(0)
6	H.K.	13	M	X150 (4)	X110 (0)	X115 (0)	X 66 (0)	X 40 (0)	X 20 (0)	X 18 (0)
7	T.T.	64	F	>X160 (13)	>X160 (0)	>X160 (0)	>X160 (0)	X110 (0)	X 51 (0)	X 40 (0)
8	S.T.	19	M	>X160 (11)	X120 (0)	X146 (0)	(0)	X 64 (0)	X 32 (0)	
9	T.S.	22	M	X 76 (4)	X 40 (0)	X 51 (0)	(0)	X 48 (8)	X 49 (6)	X 17 (0)
(Bitin-s-oxide)										
10	S.M.	12	F	>X160 (216)	>X160 (106)	>X160 (0)	>X160 (0)	>X160 (0)	X 53 (0)	X 21 (0)
11	T.I.	13	M	X 55 (18)	X 57 (0)	X 57 (0)	X 95 (0)	X 36 (0)	X 20 (0)	(0)
12	S.M.	13	M	X 44 (17)	X 40 (1)	X 22 (0)	X 14 (0)	X 15 (0)	(0)	(0)
13	O.W.	13	M	X 53 (10)	X 44 (1)	X 33 (0)	X 69 (0)		X 15 (0)	X 13 (0)
14	K.I.	14	F	X 80 (39)	(2)	X 80 (0)	X 70 (0)	X 52 (0)	X 18 (0)	
15	S.Y.	16	M	X 25 (2)	X 24 (0)	X 11 (0)	X 17 (0)	X 17 (0)	(0)	(0)
16	K.Y.	24	M	>X160 (49)	(0)	>X160 (0)	(0)	X 67 (0)	X 13 (0)	X 15 (0)
17	M.S.	13	M	X 58 (11)	X 47 (0)	X 72 (0)	X 56 (0)	X 58 (0)	X 13 (0)	X 12 (0)
18	T.H.	21	M.	>X160 (17)	(0)	>X160 (0)	(0)	X 47 (0)	(0)	

() -- Number of eggs per gram in stools.

Table 2. Changes of dilution titer of Antiserum in Complement-fixation test on the individuals before and after treatment with daily dose of 20 mg/kg of Bitin and Bitin-s-oxide.

Case No.	Name	Age	Sex	Before treatment	During treatment	Immediately after treatment	1M.	3M.	6M.
(Bitin)									
1.	S.K.	54	F	X122 (18)	X 76 (0)	X 40 (0)	X 26 (0)	X 30 (0)	- (0)
2.	H.A.	67	M	>X160 (4)	>X160 (0)	>X160 (0)	>X160 (0)		X 56 (0)
3.	M.Y.	53	M	X 20 (6)		X 20 (0)	- (0)	- (0)	- (0)
4.	T.O.	15	F	X 25 (24)	X 40 (0)	X 63 (0)			X 15 (0)
5.	T.T.	50	F	X 48 (16)	X 57 (0)	X118 (0)		X 61 (0)	
6.	H.E.	15	M.	X 15 (2)		X 10 (0)	- (0)	- (0)	- (0)
7.	H.K.	52	M	X 37 (2)			X 27 (0)	X 20 (0)	- (0)
(Bitin-s-oxide)									
8.	H.W.	52	M	>X160 (8)	>X160 (0)	X105 (0)	X 56 (0)	X 27 (0)	- (0)
9.	Z.E.	52	M	>X160 (20)	X 48 (0)	X 33 (0)	X 20 (0)	X 22 (0)	- (0)
10.	S.S.	55	M.	>X160 (2)	X129 (0)	X 57 (0)	X 17 (0)	X 27 (0)	- (0)
11.	Y.S.	14	F	X156 (10)	X 56 (31)	X 50 (0)			- (0)
12.	S.K.	68	M	X128 (6)	X 60 (0)	X107 (0)	X 56 (0)	X 53 (0)	X 58 (0)
13.	K.M.	56	F	>X160 (24)	>X160 (0)	>X160 (0)	>X160 (0)	>X160 (0)	>X160 (0)
14.	S.M.	14	F	X 11 (6)	(0)	(0)	- (0)	(0)	- (0)

() --- Number of eggs per gram in stools.

Table 3. The follow-up studies on the Chest X-ray findings of the patients treated with daily dose of 10 mg/kg of Bitin and Bitin-s-oxide.

Case No.	Name	Age	Sex	Before treatment	Immediately after treatment	1M.	3M.	6M.	12M.
(Bitin)									
1.	S.S.	9	F	l-diffused infiltrative shadow	unchanged	reduced	reduced	reduced	reduced
2.	M.M.	11	M	r-diffused infiltrative shadow	unchanged	reduced	reduced	disappeared	-
3.	H.A.	13	M	both-diffused infiltrative shadow	reduced	reduced	reduced	reduced	disappeared
5.	Y.M.	14	M	r-diffused infiltrative shadow	reduced	reduced	disappeared	-	-
6.	H.K.	13	M	r-strand shadow	unchanged	unchanged	unchanged	unchanged	reduced
7.	T.T.	64	F	r-diffused infiltrative shadow	unchanged	unchanged	reduced	reduced	reduced
8.	S.T.	19	M	l-diffused infiltrative shadow	unchanged	reduced	reduced	reduced	reduced
9.	T.S.	22	M	r-ring shadow r-diffused infiltrative shadow	unchanged unchanged	reduced reduced	unchanged reduced	reduced unchanged	reduced unchanged
(Bitin-s-oxide)									
10.	S.M.	12	F	l-ring shadow l-diffused infiltrative shadow	reduced reduced	disappeared reduced	- reduced	unchanged	reduced
12.	S.M.	13	M	r-diffused infiltrative shadow	reduced	reduced	disappeared	-	-
13.	C.N.	13	M	both-diffused infiltrative shadow	reduced	reduced	reduced	reduced	reduced
14.	A.I.	14	F	r-diffused infiltrative shadow	reduced	disappeared	-	-	-
16.	F.I.	24	M.	r-diffused infiltrative shadow	unchanged	reduced	disappeared	-	-
17.	A.S.	13	M	l-diffused infiltrative shadow	unchanged	reduced	reduced	reduced	disappeared

Table 4. Results of Intradermal test, Complement-fixation test and Stool examination.

Location	Objects	No. examined	Intradermal test (+)	Intradermal test (±)	Total	C.F.-test (+)	Eggs (+)
Takahama machi	Primary school children	704	9	10	19(2.7%)	3/19	1/19
	Middle school children	1,018	20	5	25(2.5%)	10/25	3/25
	Total	1,722	29	15	44(2.6%)	13/44 (29.5%)	4/44 (9.1%)
Shika machi	Inhabitants	1,023	18	8	26(2.5%)	4/26 (15.4%)	